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Abstract
Background: The role of surgery in the management of patients with advanced gastrointestinal stromal tumors
(GIST) in the era of imatinib mesylate (IM) remains debated. We analyzed the outcome of patients with non
metastatic locally advanced primary GIST treated with IM within the prospective BFR14 phase III trial.
Methods: The database of the BFR14 trial was searched for patients with no metastasis at time of inclusion.
Patients treated for recurrent disease were excluded. Twenty-five of 434 patients met these criteria.
Results: Fifteen of 25 patients (60%) had a partial response to IM. Nine of the 25 patients (36%) underwent surgical
resection of their primary tumor after a median of 7.3 months of IM treatment (range 3.4-12.0). Per protocol
patients received continuous IM treatment in the post resection period, in an adjuvant setting. With a median
follow-up of 53.5 months, there was a significant improvement in progression-free survival (PFS) and overall
survival (OS) for patients who underwent surgical resection versus those who did not (median not reached vs
23.6 months, p = 0.0318 for PFS and median not reached vs 42.2 months, p = 0.0217 for OS). In the group of
patients who underwent resection followed by IM, the 3-year PFS and OS rates were 67% and 89% respectively
Conclusions: Following neoadjuvant IM for non metastatic locally advanced GIST 9 of 25 patients (36%) were
selected for resection of the primary tumor. OS and PFS figures were close to those of localised intermediate or
high risk GIST (70% at 5 years) in the subgroup of operated patients, while the outcome of the non-operated
subgroup was similar to that of metastatic GIST.
Background
Gastrointestinal stromal tumors (GIST) are the most fre-
quent mesenchymal tumors of the gastrointestinal tract
and are thought to originate from the interstitial cells of
Cajal [1]. The management of advanced and metastatic
GIST has considerably improved with the use of imatinib
mesylate (IM). Approximately 50 to 70% of unselected
patients with advanced or metastatic GIST respond to
IM and the median progression-free survival (PFS) is 20
to 24 months [1,2] in a highly chemo-resistant disease
[3]. IM, originally designed as a specific inhibitor of the
Bcr-Abl kinase for the treatment of chronic myelogenous
leukaemia, was also shown to be a potent inhibitor of the
tyrosine kinase activities of KIT, PDGFR and CSF1R. KIT
or PDGFRA mutations are considered an early event in
the oncogenesis of GIST [4,5] and are found in roughly
90% of cases. IM is considered a standard of care for
patients with advanced disease and as adjuvant therapy
for completely resected localised GIST [6-8]; however,
its role in the neoadjuvant setting is currently under
investigation.
The outcome of patients with locally advanced and
unresectable GIST is generally considered to be similar
to that of patients with metastatic disease. Although
first-line treatment with IM produces high rates of dis-
ease control in patients with advanced disease, most
patients experience disease progression due to the emer-
gence of molecularly resistant clones within 2-3 years
* Correspondence: cassierp@hotmail.com
† Contributed equally
2Department of medicine, Centre Léon Bérard, 28 rue Laennec, 69008 Lyon,
France
Full list of author information is available at the end of the article
Blesius et al. BMC Cancer 2011, 11:72
http://www.biomedcentral.com/1471-2407/11/72
© 2011 Blesius et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.after treatment initiation. This observation led several
authors to investigate the value of surgical excision of
residual disease following response to IM, before the
development of secondary resistance. Several publica-
tions have reported on the feasibility of surgery follow-
ing primary treatment with IM [9-14], but little is
known about the exact benefit in terms of progression-
free or overall survival. Furthermore, all these studies
included patients with both locally advanced and meta-
static disease. All were retrospective, except the recently
reported RTOG-0132 study [11].
We report here the retrospective analysis of patients
with locally advanced non metastatic GIST who received
primary medical therapy with IM in the BFR14 prospec-
tive trial [15], with special attention to the patients who
underwent secondary surgery of their primary tumor.
Methods
BFR14 population
The BFR14 trial is a phase III trial randomizing interrup-
tion versus continuation of imatinib beyond one year of
treatment for non progressive patients [15]. After the
results of the randomisation at one year were known, the
protocol was amended to allow randomisation after three
years of treatment, and more recently after five years of
treatment [16].
Inclusion criteria were: age at least 18 years, histological
confirmation of locally advanced and/or metastatic GIST,
immunohistochemical documentation of c-KIT (CD117)
expression, and Eastern Cooperative Oncology Group per-
formance status of 0 to 3. Patients had to be previously
untreated with imatinib, with no history of previous malig-
nancy, and were required to have normal renal, cardiac,
and hepatic functions. No concurrent anticancer therapy
was allowed. All patients gave written informed consent
before inclusion.
Imatinib was given orally at 400 mg per day, as a single
daily dosing. Clinical and biological tolerance was assessed
weekly during the first month of treatment, every 2 weeks
the following month, then monthly for three months, and
every three months thereafter. Initial assessment included
a complete history, clinical examination, serum biochemis-
try, liver function test, whole blood count and computed
tomography scan (CT scan) and/or magnetic resonance
imaging (MRI) of the tumor. Imaging techniques were
repeated after 6 and 12 weeks of treatment and every
3 month thereafter. Response was graded according to the
RECIST criteria [17].
Definition of non metastatic locally advanced GIST
To be eligible for the present substudy, patients of the
BFR14 study were to have primary non metastatic GIST
as assessed by the local multidisciplinary team at each
participating site, and no prior surgery, thus excluding
patients with recurrent GIST.
Statistical analysis
Data were described using the median and range for
continuous variables and using percentages with 95%
confidence intervals for qualitative variables. Compari-
sons were performed using thec h i - s q u a r et e s t ,F i s h e r ’s
exact test, or Wilcoxon’s rank-sum test as appropriate.
Survival times were calculated from the date of entry in
the BFR14 trial (i.e. initiation of IM treatment) and were
displayed using the Kaplan-Meier method [18]. Progres-
sion-free survival (PFS) was defined as the time from
the date of inclusion (start of IM) to the date of pro-
gression on IM 400 mg/day or death. Overall survival
(OS) was defined as the time from the date of inclusion
to death of any cause. Differences in survival distribu-
tions were tested using the Log-Rank test. Differences
were considered statistically significant when p ≤ 0.05.
Statistical analyses were performed using the SPSS
12.0.1 (SPSS Inc, Chicago, IL) software package.
Results
As of April 2010, 434 patients have been included in the
BFR14 trial. Sixty patients were registered as having no
known metastasis initially. Of these 60 patients, only 25
had no previous history of surgery for GIST and were
included in the present substudy. The 35 remaining
cases included patients with locally advanced disease
who received IM as additional therapy following R2
resection or patients with locally advanced recurrent
disease.
Characteristics of these 25 patients and response to IM
are presented in Table 1. Median age was 65.5 (range
39.8-80.5) years, 16 patients were males and the median
performance status was 1 (range 0-3). Median tumor size
at baseline was 15 cm. No complete response was seen
following treatment with IM, 15 patients (60%) had a par-
tial response (PR) after a median of 4.0 (range 1.4-12.8)
months, 7 patients (28%) had stable disease (SD) as their
best response, while 3 (12%) patients had progressive dis-
ease (PD) as their best response (Figure 1).
Nine of the 25 patients (38%) underwent surgery after
a median of 7.3 (range 3.4-12.0) months of IM treat-
ment. Surgery was performed by the local surgeons who
had initially refuted operation. In 4 patients tumor
shrinkage with IM allowed resection at the price of a
less morbid operation. In 2 patients surgical resection
was performed as a salvage procedure for disease pro-
gressing on IM (primary progession in one case and
progression following initial response in another case).
The reason(s) that lead to the decision to operate each
patient are listed in table 2. Patients who underwent
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Page 2 of 7surgery tended to be younger (median 60.0 vs 69.7, p =
0.174) and have better performance status (PS) (PS 0-1
9/9 vs 11/16, p = 0.253) than the non-operated patients,
although these differences were not statistically different
(table 1). The sex ratio was similar between the two
groups. Non-operated patients were more likely to have
GIST from the peritoneum or the oesophagus (7/16 vs
1/9, p = 0.040). Baseline tumor size was comparable
between patients who were operated and those who
were not (p = 0.671, Mann and Whitney test). The
response rate was slightly superior in the operated
group (67% vs 56% in the non-operated group), but the
difference was not statistically significant (p = 0.691).
The clinical benefit rate (PR+SD) was similar in the two
groups (89% and 88%, p = 1.0). Among the 9 patients
who underwent surgery, 6 had a partial response after a
median of 4.2 months of treatment with IM, and surgery
was microscopically complete (R0) for 5 of them and
macroscopically incomplete in one of them (R2). Two
patients underwent surgery with a volumetric response
which was less than a partial response, i.e. disease stabi-
lization according to RECIST; and surgery was complete
for both of them (R0). One patient underwent surgery
while his disease was progressing according to RECIST:
surgical excision was macroscopically complete but with
positive margins, and this patient remains in complete
response (CR) 66.4 months after the procedure despite
his refusal to continue IM post-operatively. The other
eight operated patients accepted to continue IM after
surgery as specified by the study protocol. Three of
9 patients progressed 13.3, 17.0 and 24.8 months after
surgery; the other 6 patients are currently in CR at a
median of 55.4 (range 50.0-66.5) months after surgery.
With a median follow-up of 53.5 (range 4.4-77.0)
months, the median PFS is 32.1 months for the 25
patients (Figure 2), while median OS is not reached (not
shown). PFS was significantly longer (figure 3) for the
9 patients who underwent surgery after IM than for the
Table 1 Patients’ main characteristics
All Patients who
underwent surgery
Patients who
were operated
Characteristics N % N % N %
25 9 16
Age
Median
(range)
65.5
(39.8-80.5)
60.0
(39.8-80.5)
69.7
(40.7-81.9)
Gender
Male 16 64% 6 67% 10 63%
Female 9 36% 3 33% 6 38%
Tumor location 0%
Stomach 4 16% 1 11% 3 19%
Small intestine 7 28% 4 44% 3 19%
Peritoneum 7 28% 1 11% 6 38%
Oesophagus 2 8% 0 0% 2 13%
Rectum 4 16% 3 33% 1 6%
Pelvis 1 4% 0 0% 1 6%
Tumor size (mm)
Median (range) 150 (36-280) 150 (45-280) 149 (36-200)
≤ 50 2 8% 1 11% 1 6%
50 < - ≤ 100 7 28% 3 33% 4 25%
> 100 16 64% 5 56% 11 69%
WHO PS 0%
0 10 40% 4 44% 6 38%
1 10 40% 5 56% 5 31%
2 2 8% 0 0% 2 13%
3 1 4% 0 0% 1 6%
Not reported 2 8% 0 0% 2 13%
Best response to IM
PR 15 60% 6 67% 9 56%
SD 7 28% 2 22% 5 31%
PD 3 12% 1 11% 2 13%
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(median PFS not reached vs 23.6 months respectively,
p = 0.0322). Similarly, OS (figure 4) was longer for the
resected group (median OS not reached vs 29.7 months
respectively, p = 0.0154). This difference in PFS and OS
persisted when analysis was limited to patients with PR
or SD on IM, after exclusion of progressive patients,
although the difference in PFS did not reach statistical
significance in this analysis (median 29.7 vs not reached,
p = 0.0998 and 42.2 vs not reached, p = 0.0333 for PFS
and OS respectively). When analysing only the 15 patients
who had PR to IM, the median PFS was 29.7 months for
non-resected patients vs not reached for resected patients
(p = 0.2829).
Discussion
Imatinib mesylate is the new paradigm of treatment tar-
geting the initial causal molecular event in solid tumors.
However, it is still unclear whether patients with locally
advanced or metastatic disease are cured, as shown by
the results of the BFR14, which showed consistent dis-
ease progression following treatment interruption after
1, 3 and 5 years of treatment [15,16]. The role of sur-
gery during or following treatment with IM for locally
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Figure 1 Waterfall plot of patients’ best response. Dark grey bars represent patients who did not undergo resection of their primary tumor.
Light grey bars represent patient who had their primary tumor resected.
Table 2 Reasons for operation following treatment with Imatinib
Patient
N
Age at
surgery
Tumor
location
Best %
tumor
shrikage
Time to
surgery
reason for operation
4 43 Rectum -47 12,1 Significant response after 12 months on imatinib, enabling tumor resection
6 66 Mesentery -63 6,7 Large tumor lesion, decision to operate following tumor shrinkage on imatinib
7 81 Rectum -47 8,1 After initial response, patient had early signs of progression (increased blood flow on
DCE-ultrasound) and was therefore operated before actual RECIST progression
8 40 Rectum -46 7,3 Surgery enabled following tumor shrinkage
12 43 Small
bowel
-74 6,5 Surgery planned prior to treatment with imatinib (true neoadjuvant)
13 61 Small
bowel
-74 11,7 Surgery enabled following tumor shrinkage
14 71 Small
bowel
20 3,4 Rapid progression on imatinib 400 mg/d, dose increased to 600 mg/d which was
poorly tolerated, salvage surgery seemed feasible. Resection was R1
15 76 Stomach 5 4,4 No response on imatinib with poor tolerance. Following surgery this patient was
restarted on a lower dose of IM.
16 50 Small
bowel
-19 7,3 Stable disease after 6 months on imatinib, surgery was deemed feasible by surgeon.
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Page 4 of 7advanced disease remains controversial. Several expert
centers throughout the world have reported their results
with surgical resection following treatment with IM for
both locally advanced and metastatic GIST [9-14]. All
these studies are unicentric and retrospective. Most of
them have underlined the strong correlation between
the disease status regarding response to IM before sur-
gery and the outcome after surgery. Patient with multi-
f o c a lp r o g r e s s i v ed i s e a s ea tt h et i m eo fs u r g e r yh a v ea
short PFS following surgery (3-6 months), while patients
with unifocal disease progression have a 6 months med-
ian PFS with some patients remaining free of progres-
sion after long-term follow-up [12,13]. The recently
reported RTOG0132/ACRIN6665 trial [11] is the first
study to prospectively assess the role of preoperative IM
(during 8 to 12 weeks) in patients with primary locally
advanced (≥ 5 cm: 30 patients) and/or metastatic/recur-
rent (≥ 2 cm: 20 patients) GIST. In this study, toxicity
was minimal and did not modify post-operative morbid-
ity. However, because it was a single arm phase II trial,
this study did not answer the question of the benefit of
surgery in patients with locally advanced initially inoper-
able GIST.
Our present study is the first multi-centric series to
address the issue of benefit of surgery after neoadjuvant
IM in this setting. We show that among 25 patients
with non-metastatic locally advanced GIST, 9 patients
(36%) were selected to undergo surgical resection fol-
lowing primary medical treatment with IM. These
9 patients had improved PFS and OS compared to non-
operated patients, with survival rates close to those
observed for localised intermediate or high risk GIST,
whereas survival of non-operated patients was similar to
that of patients with metastatic disease. Although these
results suggest an improved outcome for operated
patients, this study has some obvious limitations. One of
these limitation is that patients were selected and not
randomised to undergo surgery and were therefore
more likely to benefit from the procedure based on
medical judgement by the investigators at each site.
Furthermore, our series is small and retrospective, pre-
cluding any definitive conclusion. As previously men-
tioned our observation is likely biased since selection of
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Figure 2 Progression-free-survival.
Figure 3 Progression-free survival according to surgical status.
Figure 4 Overall survival according to surgical status.
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Page 5 of 7patients for surgery may be linked to other prognostic
factors such as tumor location, patient’sa g e ,p e r f o r -
mance status as reflected by the differences (though not
significant) seen in our series between the operated and
non-operated groups. The response to IM may be
another source of bias as more patients had a PR in the
operated group than in the non-operated group. How-
ever, survival remained better in the operated group
even when considering only patients with partial
response or patients with clinical benefit (PR or SD).
A possible source of difference of survival between the
two groups may be the randomisation (see the “patients
and methods” section). Six of 25 patients were rando-
mised, two in the IM continuation arm and four in the
interruption arm. All of the four patients randomised to
interruption were in the non surgical group, therefore
introducing a bias. However, PFS and OS were still sig-
nificantly better in the surgery group when these four
cases were removed from analysis (9.0 months vs med-
ian not reached p = 0.0037 and 26.3 months vs median
not reached, p = 0.0128 respectively for PFS and OS).
Another bias source of this multicentric study lies in
the inclusion criterion of initial unresectability, which
was left at the treating physician’s discretion. Therefore,
some patients may have had truly unresectable disease,
while others may have had disease that was actually
resectable at the price of a major procedure, in which
case primary medical treatment appeared to be the best
option. Resectability, before and after IM, was assessed
by multidisciplinary teams, including surgeons expert in
GIST management.
Conclusions
Overall, this and other reports can not lead to any defi-
nitive conclusion regarding the benefit of surgery in
patients with locally advanced GIST treated with IM.
This benefit can only be demonstrated in randomised
prospective trials, which are ongoing in the metastatic
setting. However, since patients with locally advanced
disease who become operable following IM appear to
benefit from resection of the primary tumor, we think
that surgery should be proposed, or at least discussed,
in this subgroup of patients when the disease no longer
responds to IM.
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